The PCOS diagnostic market offers various blood tests and ultrasound screening for detection of polycystic ovary syndrome (PCOS). Blood tests help detect high levels of male hormones and problems with blood sugar and insulin levels. Ultrasound screening helps detect enlarged ovaries with small cysts on the outer edges, a characteristic of PCOS. The global PCOS diagnostic Market is estimated to be valued at US$ 620 million in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advances in diagnostic methods are driving the growth of the PCOS diagnostic market during the forecast period. Traditionally, diagnosis of PCOS involved physical examination, checking symptoms, blood tests, and ultrasounds. However, new diagnostic methods are being introduced that help diagnose PCOS more accurately at an early stage. For example, innovations in ultrasound technology now allow imaging of ovaries and detection of small cysts with more clarity. Additionally, advancement in blood testing methods now enable detection of specific hormonal biomarkers that indicate PCOS with higher sensitivity and specificity. Introduction of such improved diagnostic methods is increasing the early detection and diagnosis rate of PCOS, thus accelerating the growth of PCOS diagnostic market during the forecast period.
Segment Analysis
The global PCOS diagnostic market is dominated by the hormonal testing segment, which accounted for over 30% market share in 2022. Hormonal testing helps in detecting hormonal imbalances that are at the root of Polycystic Ovary Syndrome (PCOS). It gauges levels of key hormones such as testosterone, estrogen, progesterone, LH and FSH that influence the menstrual cycle and development of cysts in the ovaries. As hormonal testing offers reliable and cost-effective diagnosis of PCOS, its demand continues to grow at a steady pace.
Key Takeaways
The global PCOS diagnostic market is expected to witness high growth over the forecast period of 2023 to 2030. Growing awareness about early diagnosis and management of PCOS and increasing popularity of hormone testing are fueling the market expansion.
Regional analysis: North America currently dominates the global PCOS diagnostic market due to high disease prevalence coupled with advanced healthcare infrastructure and growing healthcare expenditure in the region. The market is experiencing the fastest growth in Asia Pacific on account of improving access to diagnostic technologies and rising medical tourism in countries such as India and China.
Key players operating in the PCOS diagnostic market are Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics, bioMérieux SA, and F. Hoffmann-La Roche Ltd. Thermo Fisher Scientific offers a comprehensive menu of hormonal diagnostic tests for PCOS. Abbott provides PCOS diagnostic analysis instruments and tests kits for hospitals and diagnostic centers.
No comments:
Post a Comment